Investor Area


Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

Sunday, 14 August 2016

CLINUVEL Newsletter – August 2016

16 August 2016   In the arduous journey from explorative concept to development to commercial availability of the novel molecular entity – SCENESSE® afamelanotide 16mg)1 – one may become engrossed in the processes leading to the desired outcome. The ultimate goal of changing people’s lives is what drives us at Clinuvel and our team is […]

Download PDF
Tuesday, 09 August 2016

Notice of Initial Substantial Holder

10 August 2016 Enclosed are the details of a notice of initial substantial holder. Download PDF for more

Download PDF
Wednesday, 03 August 2016

Appendix 3Y

03 August 2016   We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.    Download PDF for more

Download PDF
Tuesday, 02 August 2016

Appendix 3B

02 August 2016   New issue announcement, application for quotation of additional securities and agreement   Download PDF for more

Download PDF

02 August 2016   CLINUVEL prepares New Drug Application (NDA) for the treatment of erythropoietic protoporphyria (EPP) Executive summary: FDA requirement for combination therapy model replicating clinical studies protocol in vitiligo fulfilled Safety of the combination therapy confirms observations in clinical trials CUV102 and CUV103 CLINUVEL will request a guidance meeting with the FDA to […]

Download PDF
Thursday, 28 July 2016

Appendix 4C – Q4 FY16

28 July 2016   Enclosed is a copy of the quarterly report for the period ending 30 June 2016   Download PDF for more

Download PDF

17 July 2016   Clinuvel prepares New Drug Application (NDA) for the treatment of erythropoietic protoporphyria (EPP) Executive summary: FDA concludes initial review of datasets on SCENESSE® in EPP FDA deems datasets satisfactory for submission of New Drug Application Pre-NDA meeting with FDA to be scheduled to discuss timelines and procedure Clinuvel will request rolling […]

Download PDF

05 July 2016   Executive summary: FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPP NDA filing allowed on a rolling basis FDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment Clinuvel Pharmaceuticals [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that the […]

Download PDF

20 June 2016   First commercial delivery, SCENESSE® approved as standard of care in the Netherlands. CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its drug SCENESSE® (afamelanotide 16mg) has been launched in Europe, with the first commercial delivery of the product under European marketing authorisation. Patients with the rare genetic disorder […]

Download PDF

 31 May 2016   CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced the inclusion of its Sponsored Level 1 American Depository Receipt (ADR) program in Nasdaq’s International Designation, a new visibility offering available to non-US companies. CLINUVEL is the first life science company to be selected for this initiative, first launched by […]

Download PDF
Tuesday, 17 May 2016

SCENESSE® treatment in Europe

17 May 2016   German Porphyria Expert Centres to start distribution of SCENESSE® (afamelanotide 16mg) Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced an update on the company’s post-authorisation distribution of SCENESSE® (afamelanotide 16mg) across Europe for adult patients with the rare disorder erythropoietic protoporphyria (EPP).   Download PDF for more

Download PDF
Friday, 29 April 2016

Appendix 4C – Q3 FY16

29 April 2016   Enclosed is a copy of the quarterly report for the period ending 31 March 2016.   Download PDF for more

Download PDF
Monday, 11 April 2016

Form 604

11 April 2016   Enclosed is a notice of change of interests of substantial holder   Download PDF for more

Download PDF
Monday, 04 April 2016

CLINUVEL Newsletter – April 2016

4 April 2016   Clinuvel is arriving at a point many of our patients and investors have longed for: first commercial treatment for EPP patients. Last month our European teams conducted a number of training and accreditation visits at European Hospitals. The purpose of these site visits was to instruct staff, management and clinical personnel […]

Download PDF

23 March 2016   NICE’s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria (EPP) Executive summary SCENESSE® evaluated as part of the Highly Specialised Technologies Programme (HST) in UK HST Programme review of relatively high cost – low volume technology Evaluation of the drug as an innovative therapy for unmet […]

Download PDF
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019  Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead. FDA REVIEWAt the time of print CLINUVEL will find itself …

Download PDF
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. …

Download PDF
Tuesday, 15 January 2019

CLINUVEL Newsletter - January 2019

15 January 2019 Dear patients, shareholders, friends,I wish you all a year in good physical and spiritual health, and a year in which we anticipate further progress of SCENESSE ® (afamelanotide 16mg)1 and CLINUVEL’s other products …

Download PDF
Thursday, 10 January 2019

US FDA sets PDUFA date for SCENESSE®

Melbourne, Australia 10 January 2019 Priority Review granted for innovative drug, PDUFA date 8 July 2019  Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in …

Download PDF
Wednesday, 19 December 2018

CLINUVEL Vitiligo Communiqué

19 December 2018 As a depigmentation disorder (hypomelanosis), vitiligo is the most well-known of all leucodermatoses (“white skin”) whereby other variants of loss of skin pigmentation – temporary or permanent - are described as albinism, piebaldism, …

Download PDF
Monday, 17 December 2018

CLINUVEL Newsletter - December 2018

17 December 2018 As the year draws to a close we look back at a hectic, yet successful, 12 months. In CLINUVEL’s marathon, the past year looked like a series of endless sprints to accomplish all we had …

Download PDF
Monday, 05 November 2018

CLINUVEL Newsletter - November 2018

05 November 2018 The most recent quarterly financial results (1 July-30 September 2018) confirm the steady growth in clinical demand for SCENESSE® (afamelanotide 16mg) in erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder.1 EPP is classified …

Download PDF
Friday, 05 October 2018

Chair Letter to Shareholders

05 October 2018 This is a thank you to shareholders, investors, patients, clinicians, and all those who have continued to support CLINUVEL together with new shareholders who have recently gained confidence to join the CLINUVEL register. …

Download PDF